2.07
-0.15 (-6.76%)
| Penutupan Terdahulu | 2.22 |
| Jumlah Dagangan | 300,143 |
| Harga / Pendapatan (P/E Ke hadapan) | 13.06 |
| Harga / Jualan (P/S) | 10.21 |
| Harga / Buku (P/B) | 5.07 |
| Julat 52 Minggu |
| Margin Keuntungan | -184.04% |
| Margin Operasi (TTM) | -1,956.57% |
| EPS Cair (TTM) | -0.650 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -92.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.46% |
| Nisbah Semasa (MRQ) | 1.53 |
| Aliran Tunai Operasi (OCF TTM) | 46.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 57.57 M |
| Pulangan Atas Aset (ROA TTM) | -17.07% |
| Pulangan Atas Ekuiti (ROE TTM) | -43.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | AC Immune SA | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 0.8 |
| Persekitaran Makro | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | -0.35 |
|
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 38.01% |
| % Dimiliki oleh Institusi | 26.12% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Wells Fargo & Company/Mn | 30 Jun 2026 | 1,004,041 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |